Preoperative medication use and development of postoperative delirium and cognitive dysfunction

Maria Heinrich1,2 | Anja Nottbrock1 | Friedrich Borchers1 | Rudolf Mörgeli1 | Jochen Kruppa2,3 | Georg Winterer1,4,5 | Arjen J. C. Slooter6,7 | Claudia Spies1
on behalf of the BioCog Consortium

1Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
2Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
3Institute of Medical Informatics, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
4Pharmaimage Biomarker Solutions GmbH, Berlin, Germany
5Experimental and Clinical Research Center (ECRC), Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
6Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
7UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Correspondence
Claudia Spies, Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany.

Abstract
Postoperative delirium (POD) and postoperative (neuro-)cognitive disorder (POCD) are frequent and serious complications after operations. We aim to investigate the association between pre-operative polypharmacy and potentially inappropriate medications and the development of POD/POCD in elderly patients. This investigation is part of the European BioCog project (www.biocog.eu), a prospective multicenter observational study with elderly surgical patients. Patients with a Mini-Mental State Examination score less than or equal to 23 points were excluded. POD was assessed up to 7 days after surgery using the Nursing Delirium Screening Scale, Confusion Assessment Method (for the intensive care unit [ICU]), and a patient chart review. POCD was assessed 3 months after surgery with a neuropsychological test battery. Pre-operative long-term medication was evaluated in terms of polypharmacy (≥5 agents) and potentially inappropriate medication (defined by the PRISCUS and European list of potentially inappropriate medications [EU(7)-PIM] lists), and associations with POD and POCD were analyzed using logistic regression analysis. Eight hundred thirty-seven participants were included for analysis of POD and 562 participants for POCD. Of these, 165 patients (19.7%) fulfilled the criteria of POD and 60 (10.7%) for POCD. After adjusting for confounders, pre-operative polypharmacy and intake of potentially inappropriate medications could not be shown to be associated with the development of POD nor POCD. We found no associations between pre-operative polypharmacy and potentially inappropriate medications and development of POD and POCD. Future studies should focus on the evaluation of drug interactions to determine whether patients benefit from a pre-operative adjustment.

Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Polypharmacy and drugs listed on PRISCUS or European list of potentially inappropriate medications (EU(7)-PIM) lists are associated with higher hospitalization rates, increased morbidity, and poorer outcome regarding quality of life. Studies examining
INTRODUCTION

Postoperative delirium (POD) is an acute and sudden change in the mental state, characterized by fluctuating levels of attention, consciousness, and cognition. The occurrence of POD is associated with increased complication and mortality rates, and may be related to the development of mild and major postoperative (neuro-)cognitive disorder (POCD).

Incidence depends on predisposing and precipitating risk factors. Age-related changes in brain metabolism, such as neurodegeneration, neurotransmitter imbalances, microcirculation disorders, altered penetration of the blood-brain-barrier, and modulations in intracellular signal transduction, increase the vulnerability of the brain to stress factors. Therefore, older people are particularly susceptible to POD.

At the same time—due to the accumulation of comorbidities—an increasing amount of medication is prescribed to elderly patients. Polypharmacy and potentially inadequate medication may have an additional influence on cognition. Although there is no uniform definition for polypharmacy, it is generally described in literature as the long-term intake of greater than or equal to 5 prescription-free and/or prescription drugs. To address the increased risk of adverse drug reactions, especially for older people, the German PRISCUS list was published in 2010, which served as basis for the 2015 European list of potentially inappropriate medications (EU(7)-PIM). Drugs from the PRISCUS and EU(7)-PIM lists should be avoided whenever possible in elder patients. It has been shown that patients with polypharmacy and drugs listed on the PRISCUS or EU(7)-PIM lists have a higher hospitalization rate due to adverse drug events, have poorer outcome in terms of quality of life, and an increased morbidity after hospitalization.

Awareness and modulation of predisposing and precipitating risk factors in pre-operative, intra-operative, and postoperative settings are crucial for the prevention of POD and POCD. Prevention strategies can reduce the in-hospital incidence of delirium by 30%–40%. Although former studies in the field of peri-operative medicine focused on the relationship of POD and polypharmacy, there is still a lack of studies using a structured assessment of long-term medication in terms of potentially inadequate medication, according to the PRISCUS and EU(7)-PIM lists, in addition to polypharmacy, on the development of POD and POCD. If the application of the lists or the screening for polypharmacy can reliably identify patients at risk for the development of POD and POCD, severe implications can be prevented or reduced through the early initiation of primary prevention strategies.

In this study, we aim to investigate the association between pre-operative polypharmacy and potentially inappropriate medications (defined by the PRISCUS and EU(7)-PIM lists) and the development of POD and POCD in elderly patients.

METHODS

Study design and population

This investigation was performed as part of the BioCog project (www.biocog.eu), a prospective multicenter observational study conducted at the Charité – Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care.
Medicine, Berlin, Germany, and the University Medical Center Utrecht, Department of Intensive Care Medicine, Utrecht, The Netherlands. The BioCog study aims to establish biomarker panels for risk and clinical outcome prediction of POD and POCD. The study was approved by the local Ethics Committees (ref.: EA2/092/14 and 14–469), and conducted in accordance with the Declaration of Helsinki (ClinicalTrials.gov: NCT02265263). Written informed consent was obtained from each patient, and all local data privacy regulations were followed.

We included patients aged greater than or equal to 65 years of European descent, who underwent elective surgery with an expected surgical duration greater than or equal to 60 min, provided they were able to provide informed consent, and could undergo magnetic resonance imaging. We excluded patients with a Mini-Mental State Examination score less than or equal to 23 points, homeless patients, and others who could not be reached by telephone or postal services for follow-up examinations. In addition, we excluded patients enrolled in other prospective interventional studies, those who were accommodated in an institution due to an official or judicial order, and patients with conditions limiting the conduction of neurocognitive testing, such as neuropsychiatric disease, anacusis/hypoacusis, and language barriers.

Baseline measurements

The following baseline measurements were collected to describe the study population: age, sex, physical status according to the American Society of Anesthesiologists Physical Status (ASA PS), Charlson Comorbidity Index (CCI), pre-existing neurocognitive disorder (NCD; for details see Supplementary Material), frailty status (for details see Supplementary Material), duration of anesthesia, site of surgery (intrathoracic/-abdominal/-pelvic, peripheral, and intracranial operations), and education according to the International Standard Classification of Education (ISCED). In addition, Geriatric Depression Scale was recorded 3 months after surgery.

Postoperative delirium

POD was defined according to the 5th edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria. Patients were considered delirious in case of:

- greater than or equal to 2 cumulative points on the Nursing Delirium Screening Scale (Nu-DESC) and/or
- a positive Confusion Assessment Method (CAM) score and/or
- a positive CAM for the ICU (CAM-ICU) and/or
- patient chart review that showed descriptions of delirium (e.g., confused, agitated, drowsy, disorientated, delirious, and received antipsychotic therapy).

Delirium screening was started in the recovery room and repeated twice per day at 08:00 and 19:00 (∓1 h) up to 7 days after surgery. Delirium assessment was conducted independently of the routine hospital procedures by a research team, which was trained and supervised by psychiatrists and delirium experts.

Postoperative cognitive dysfunction

To identify POCD, a neuropsychological test battery consisting of noncomputerized and computerized tests was performed before surgery, at discharge from the hospital or on the seventh postoperative day, and 3 months after surgery. The composition and retest reliabilities of the test battery are described in an additional publication. Trained doctoral students and study nurses performed the testing based on a standard operating procedure, which was approved by two neuropsychologists.

POCD was defined using an R algorithm described in another publication that applied the Reliable Change Index (RCI) with the International Analysis of Postoperative Cognitive Dysfunction (ISPOCD) criteria proposed by Rasmussen. Missing values that were attributable to technical difficulties or external disturbances were imputed at random using the missForest package in R software environment (R Core Team 2017; R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/). Missing information due to disturbed attention or confusion of the patients (e.g., inability to understand standardized test instructions) for some but not all tests were imputed with the value of the worst performance.

Long-term medication

The pre-operative long-term medication was assessed during the pre-operative anesthesia consultation by means of anamnesis, patient’s medical record, or medication prescriptions. Long-term medication included both prescription and prescription-free drugs, which were taken regularly at the time of the consultation. Long-term medication was evaluated with regard to polypharmacy and potentially inappropriate medication. Polypharmacy was defined as greater than or equal to 5 agents and potentially inappropriate medication was defined according to the PRISCUIS12 and EU(7)-PIM lists. An initial analysis merely regarded the presence of polypharmacy and the intake of (any) potentially inappropriate medication. This was followed by an analysis to
consider the number of regularly taken medication and the
number of potentially inadequate agents.

For a descriptive analysis, the pre-operative long-term
medication was additionally divided into groups according
to the Anatomic Therapeutic Chemical (ATC) classification
system.24

Statistical analysis

Baseline characteristics were expressed as median and
lower and upper quartile, or frequencies with percentages.
Differences between the groups were tested using Mann-
Whitney U test or χ² test.

The associations between pre-operative polypharmacy
and potentially inappropriate medications (defined by the
PRISCUS and EU(7)-PIM lists) and the development of POD
and POCD were investigated using multivariable logistic re-
gression analysis, adjusting for possible confounding vari-
ables. Confounders were chosen a priori and included age,
CCI, frailty status, pre-existing NCD, duration of anesthesia
and site of surgery for the regression analysis of POD, and
age, ASA PS, frailty status, depression 3 months after sur-
gery (defined as >4 points in GDS), and education (accord-
ing to ISCED, with regard to levels 1–4, which corresponds
to a lower educational level) for the regression analysis of
POCD. A separate regression analysis was performed for
each investigated variable (polypharmacy, potentially inap-
propriate medication, number of agents, and the number of
potentially inadequate agents according to the PRISCUS and
EU(7)-PIM lists). No adjustments were made for multiple
testing.

All analyses were performed with IBM SPSS Statistics,
version 23 (Copyright 1989, 2015 by SPSS Inc., Chicago, IL)
and in R software environment.

RESULTS

From October 2014 to April 2017, 1033 participants were
enrolled at 2 study centers (Berlin, Germany and Utrecht,
The Netherlands). Accounting for early dropouts, missing
data, and loss to follow-up, 837 participants could be in-
cluded for analysis of POD and 562 participants for analy-
sis of POCD (see Figure 1). Of these, 165 patients (19.7%)
fulfilled the criteria of POD and 60 (10.7%) for POCD (see
Tables 1 and 2). Patients with POD were significantly older,
had higher ASA PS and CCI scores, and longer duration
of anesthesia. In addition, there were group differences re-
garding to frailty status and site of surgery. Patients with
POCD were older, had higher ASA PS scores, and were
found to fulfill frailty criteria more often than patients with-
out POCD. Patients with POCD did not differ in sex, CCI,
duration of anesthesia, and site of surgery compared with
patients without POCD.

Operations were most frequently performed on the mus-
culoskeletal system (27.8%) and digestive tract (18.5%; see
Table S1 for additional information). Surgical procedures

FIGURE 1  Flow Chart. POCD, postoperative delirium; POD, postoperative
(neuro-)cognitive disorder
were categorized into three types prior to analysis, whereas 43.4% of all operations were intrathoracic, -abdominal, or pelvic, 55.5% were peripheral, and 1.1% were intracranial.

Information on long-term medication was available for 838 patients. Only 87 patients did not take any medication, and the remaining 751 patients with long-term medication took

| TABLE 1 | Patient characteristics for POD analysis (n = 837) |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Characteristic** | **POD (n = 165)** | **No POD (n = 672)** | **p value** |
| Age [years]  | 74 [70; 77] | 71 [68; 75] | <0.001<sup>a</sup> |
| Sex | Female 79 (47.9%) | 283 (42.1%) | 0.180<sup>b</sup> |
| ASA PS | 1–2 77 (46.7%) | 463 (68.9%) | <0.001<sup>b</sup> |
| | 3–4 88 (53.3%) | 209 (31.1%) | |
| CCI | 1.86 ± 1.5 | 1.31 ± 1.5 | <0.001<sup>a</sup> |
| Pre-existing NCD | No NCD 102 (69.4%) | 462 (76.7%) | 0.176<sup>b</sup> |
| | Mild NCD 25 (17.0%) | 80 (13.3%) | |
| | Major NCD 20 (13.6%) | 60 (10.0%) | |
| Frailty status | Robust 37 (22.7%) | 256 (38.6%) | <0.001<sup>b</sup> |
| | Pre-frail 87 (53.4%) | 337 (50.8%) | |
| | Frail 39 (23.9%) | 71 (10.7%) | |
| Duration of anesthesia [min] | 306 [211–473] | 168 [105–255] | <0.001<sup>a</sup> |
| Site of surgery | Intracranial 2 (1.2%) | 8 (1.2%) | <0.001<sup>b</sup> |
| | Intrathoracic/-abdominal/-pelvic 105 (63.6%) | 248 (36.9%) | |
| | Peripheral 58 (35.2%) | 416 (61.9%) | |
| Polypharmacy | 88 (53.3%) | 285 (42.4%) | 0.011<sup>b</sup> |
| Medication (PRISCUS list) | 22 (11.6%) | 78 (13.3%) | 0.540<sup>b</sup> |
| Medication (EU(7)-PIM list) | 98 (59.4%) | 319 (47.5%) | 0.006<sup>b</sup> |
| Number of agents | 5.41 ± 3.7 | 4.44 ± 3.8 | 0.002<sup>a</sup> |
| Number of agents according to PRISCUS list | 0.16 ± 0.4 | 0.13 ± 0.4 | 0.503<sup>a</sup> |
| Number of agents according to EU(7)-PIM list | 0.96 ± 1.0 | 0.78 ± 1.0 | 0.008<sup>a</sup> |

**Note:** Data are expressed as median [25th quartile; 75th quartile], or as mean ± SD except for categorical data, which are expressed as frequencies (percentages). Any p ≤ 0.05 was considered as statistically significant.

**Abbreviations:** ASA PS, physical status according to the American Society of Anesthesiologists; CCI, Charlson Comorbidity Index; EU(7)-PIM, European list of potentially inappropriate medications; NCD, neurocognitive disorder; POD, postoperative delirium.

<sup>a</sup>The p values refer to the Mann–Whitney U test between patients with or without POD.

<sup>b</sup>The p values refer to the χ² test between patients with or without POD.

| TABLE 2 | Patient characteristics for POCD analysis (n = 562) |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Characteristic** | **POCD (n = 60)** | **No POCD (n = 502)** | **p value** |
| Age [years]  | 74 [70; 79] | 72 [68; 75] | 0.001<sup>a</sup> |
| Sex | Female 28 (46.7%) | 197 (39.2%) | 0.267<sup>b</sup> |
| ASA PS | 1–2 32 (53.3%) | 361 (71.9%) | 0.003<sup>b</sup> |
| | 3–4 28 (46.7%) | 141 (28.1%) | |
| CCI | 1.52 ± 1.6 | 1.19 ± 1.4 | 0.075<sup>a</sup> |
| Frailty status | Robust 20 (33.3%) | 204 (41.0%) | 0.008<sup>b</sup> |
| | Pre-frail 27 (45.0%) | 249 (50.1%) | |
| | Frail 13 (21.7%) | 44 (8.9%) | |
| Duration of anesthesia [min] | 179 [100; 294] | 188 [117; 277] | 0.476<sup>a</sup> |
| Site of surgery | Intracranial 2 (3.3%) | 3 (0.6%) | 0.101<sup>b</sup> |
| | Intrathoracic/-abdominal/-pelvic 23 (38.3%) | 204 (40.6%) | |
| | Peripheral 35 (58.3%) | 295 (58.8%) | |
| Polypharmacy | 32 (53.3%) | 206 (41.0%) | 0.068<sup>b</sup> |
| Medication (PRISCUS list) | 9 (15.0%) | 66 (13.1%) | 0.690<sup>b</sup> |
| Medication (EU(7)-PIM list) | 30 (50.0%) | 235 (46.8%) | 0.640<sup>b</sup> |
| Number of agents | 5.50 ± 4.0 | 4.32 ± 3.3 | 0.032<sup>a</sup> |
| Number of agents according to the PRISCUS list | 0.15 ± 0.4 | 0.14 ± 0.4 | 0.719<sup>a</sup> |
| Number of agents according to the EU(7)-PIM list | 0.95 ± 1.2 | 0.75 ± 1.0 | 0.285<sup>a</sup> |

**Note:** Data are expressed as median [25th quartile; 75th quartile], or as mean ± SD except for categorical data, which are expressed as frequencies (percentages). Any p ≤ 0.05 was considered as statistically significant.

**Abbreviations:** ASA PS, physical status according to the American Society of Anesthesiologists; CCI, Charlson Comorbidity Index; EU(7)-PIM, European list of potentially inappropriate medications; POCD, postoperative cognitive dysfunction.

*The p values refer to the Mann–Whitney U test between patients with or without POCD.

*The p values refer to the χ² test between patients with or without POCD.
a median of 4 agents (3851 agents in total; see Table S2). Usually, no adjustment of medication was made at admission. Pantoprazole was the most frequently taken medication (5%), followed by metoprolol (4.2%), simvastatin (4.0%), hydrochlorothiazide (3.2%), levothyroxine (3.2%), and acetylsalicylic acid (2.9%). As shown in Figures 2 and 3, the distribution of the frequencies of the agents did not differ with respect to POD and POCD.

Overall, 45% of all patients (n = 838) fulfilled the criteria for polypharmacy, 11.9% took potentially inappropriate medication according to the PRISCUS list, and 49.8% according to EU(7)-PIM list. The most common inappropriate drug taken according to the PRISCUS list were amitriptyline (18.2%), doxazosin (12.7%), and temazepam (8.2%). According to the EU(7)-PIM list, pantoprazole (28.3%), omeprazole (7.6%), and spironolactone (3.8%) were the most commonly consumed drugs.

When analyzing group differences, patients with POD were more often affected by polypharmacy and more often took potentially inappropriate medication according to the EU(7)-PIM list (see Table 1). Furthermore, patients with POD took more agents in general, as well as more agents according to the EU(7)-PIM list. There were no group differences with regard to the PRISCUS list. In the multivariable logistic regression analysis, none of the investigated variables (polypharmacy, potentially inappropriate medication according to the PRISCUS and EU(7)-PIM lists, number of agents, and number of agents according to the PRISCUS and EU(7)-PIM lists) associated with POD reached a level of significance (see Table 3). However, in each regression model, age, duration of anesthesia, positive frailty criteria, and intrathoracic/-abdominal/-pelvic operations (vs. peripheral operations) were significantly associated with POD.

When analyzing group differences, patients with POCD took more agents in general. No other group differences between POCD and non-POCD could be identified regarding polypharmacy or potentially inappropriate medication (see Table 2). Similarly, in the multivariable logistic regression analysis, none of the investigated variables displayed an association with POCD (see Table 4). However, in each regression model, age and ASA PS were significantly and consistently associated with POCD.

**DISCUSSION**

This study aimed to investigate the association between preoperative polypharmacy and the intake of potentially inappropriate medications (defined by the PRISCUS and EU(7)-PIM lists)
lists) and the development of POD and POCD in elderly patients. This investigation included patients undergoing elective surgery across a wide range of surgical disciplines.

After adjustment for confounding factors, pre-operative polypharmacy and the intake of potentially inappropriate medications could not be shown to be associated with the development of POD or POCD. Incidences within our study sample were comparable with other cohorts, with nearly 20% of patients developing POD and nearly 10% developing POCD. Overall, 45% of all patients were affected by polypharmacy. This is in line with other studies investigating elderly patients in peri-operative context. In our cohort, 12% took potentially inappropriate medication according to the PRISCUS list. The German PRISCUS list was created with a selective literature search, an analysis of prescriptions, and includes international PIM lists, and a Delphi survey in two rounds. The list contains 282 drugs. When the PRISCUS list was introduced in 2010, prescriptions practices according to the EU(7)-PIM list in our cohort, compared with apixaban and zopiclone in a Swedish cohort, benzodiazepines, proton pump inhibitors, and tramadol in a Croatian cohort, and proton pump inhibitors, benzodiazepines, and glibenclamide in a Brazilian cohort. In addition, the observed difference between the prevalences according to the PRISCUS and EU(7)-PIM lists, and that in the simple group comparison patients with POD took drugs from the EU(7)-PIM list more frequently. Furthermore, prevalence of inadequate medication according to the EU(7)-PIM list varies considerably in literature, with values fluctuating between 37% and 81%. Similarly to the above described trend, a declining prevalence could be observed in studies conducted after the introduction of the EU(7)-PIM list in 2015. Large national differences in the prescription of agents listed on the (internationally available) EU(7)-PIM list have been reported. For example, the prescription prevalence of drugs listed on the EU(7)-PIM list was 41% in a Swedish cohort, 60% in a Brazilian cohort, and 80% in a Belgian cohort. Differences might be explained in part by the age of the respective cohorts (≥80 years in the Belgian study). Furthermore, differences in prescriptions are related to regional differences in guidelines and the availability of drugs. In contrast to the German PRISCUS list, the internationally known EU(7)-PIM list must consider location as a factor when comparing studies. Pantoprazole, omeprazole, and spironolactone were the most commonly consumed drugs according to the EU(7)-PIM list in our cohort, compared with apixaban and zopiclone in a Swedish cohort, benzodiazepines, proton pump inhibitors, and tramadol in a Croatian cohort, and proton pump inhibitors, benzodiazepines, and glibenclamide in a Brazilian cohort.

### Table 3: Multivariable logistic regression analysis regard to POD

<table>
<thead>
<tr>
<th>Term</th>
<th>OR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polypharmacy</td>
<td>1.076 [1.070; 1.639]</td>
<td>0.732</td>
</tr>
<tr>
<td>Medication (PRISCUS list)</td>
<td>0.924 [0.911; 1.070]</td>
<td>0.794</td>
</tr>
<tr>
<td>Medication (EU(7)-PIM list)</td>
<td>1.217 [0.791; 1.873]</td>
<td>0.371</td>
</tr>
<tr>
<td>Number of agents</td>
<td>1.025 [0.964; 1.089]</td>
<td>0.431</td>
</tr>
<tr>
<td>Number of agents according to PRISCUS list</td>
<td>1.017 [0.619; 1.672]</td>
<td>0.947</td>
</tr>
<tr>
<td>Number of agents according to EU(7)-PIM list</td>
<td>0.949 [0.792; 1.137]</td>
<td>0.569</td>
</tr>
</tbody>
</table>

**Note:** Entered variables into analysis: age (years), CCI, frailty status, pre-existing neurocognitive disorder, duration of anesthesia, and site of surgery. Data are expressed as OR and 95% CI. Any p ≤ 0.05 was considered as statistically significant. A separate regression analysis was performed for each investigated variable (polypharmacy, medication [PRISCUS list], medication [EU(7)-PIM list], number of agents, number of agents according to PRISCUS or EU(7)-PIM list).

**Abbreviations:** CI, confidence interval; CCI, Charlson Comorbidity Index; EU(7)-PIM, European list of potentially inappropriate medications; OR, odds ratio; POD, postoperative delirium.

### Table 4: Multivariable logistic regression analysis regard to POCD

<table>
<thead>
<tr>
<th>Term</th>
<th>OR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polypharmacy</td>
<td>0.971 [0.497; 1.896]</td>
<td>0.931</td>
</tr>
<tr>
<td>Medication (PRISCUS list)</td>
<td>1.139 [0.497; 2.608]</td>
<td>0.759</td>
</tr>
<tr>
<td>Medication (EU(7)-PIM list)</td>
<td>0.564 [0.288; 1.105]</td>
<td>0.095</td>
</tr>
<tr>
<td>Number of agents</td>
<td>1.018 [0.928; 1.117]</td>
<td>0.702</td>
</tr>
<tr>
<td>Number of agents according to PRISCUS list</td>
<td>0.969 [0.466; 2.015]</td>
<td>0.933</td>
</tr>
<tr>
<td>Number of agents according to EU(7)-PIM list</td>
<td>0.932 [0.706; 1.229]</td>
<td>0.616</td>
</tr>
</tbody>
</table>

**Note:** Entered variables into analysis: age (years), ASA PS, frailty status, depression 3 months after surgery (defined as >4 points in GDS) and education (according to ISCED, with regard to level 1–4 which corresponds to a lower educational level). Data are expressed as OR and 95% CI. Any p ≤ 0.05 was considered as statistically significant. A separate regression analysis was performed for each investigated variable (polypharmacy, medication [PRISCUS list], medication [EU(7)-PIM list], number of agents, number of agents according to PRISCUS or EU(7)-PIM list).

**Abbreviations:** ASA PS, physical status according to the American Society of Anesthesiologists; CI, confidence interval; EU(7)-PIM, European list of potentially inappropriate medications; GDS, Geriatric Depression Scale; ISCED, International Standard Classification of Education; OR, odds ratio; POCD, postoperative (neuro-)cognitive dysfunction.
application of the national PRISCUS list shows differences within Germany. Although in our cohort amitriptyline, doxazosin, and temazepam were the most commonly consumed drugs, according to the PRISCUS list, zopiclone and lorazepam, or zopiclone, zolpidem, and amitriptyline were reported as most common agents in two other German cohorts. In our view, the differences can be explained not only by regional conditions but also by the age and setting of the cohorts. Our study is, to the best of our knowledge, the only one which analyze a peri-operative cohort. On the other hand, the most frequently used substance classes in general, as well as the frequency of use, are comparable to other European cohorts. Interestingly, older patients in American cohorts, for example, tend to take significantly more medication than their European counterparts.

So far, there is no evidence that the drugs most frequently taken in our cohort (pantoprazole, metoprolol, simvastatin, hydrochlorothiazide, levothyroxine, acetylsalicylic acid, omeprazole, spironolactone, or doxazosin) could be associated with the development of POD or POCD. According to current hypotheses, only amitriptyline and temazepam would promote delirium through their anticholinergic effects. So, currently, there are no investigations on temazepam. For amitriptyline, no association could be confirmed in another study.

In our analysis, special attention should be given to the fact that the incidences of POD and POCD depend on predisposing and precipitating risk factors that are often inter-related. According to the evidence-based and consensus-based guideline on postoperative delirium of the European Society of Anaesthesiology, advanced age and comorbidities are predisposing factors, whereas duration and site of surgery are precipitating risk factors for POD. Advanced age and comorbidities are also risk factors for POCD, in addition to alcohol abuse, low education level, or perioperative complications. This is also reflected in our results. In addition, we could not find any group differences between patients with POCD and without POCD regarding duration of anesthesia or site of surgery. In this context, it should be noted that there are also indications in the literature that POD and POCD co-occur and share risk factors, but their relationship remains unclear. In addition, a biphasic pattern was described in the relationship between POD and POCD. Here, we observed that the cognitive performance of patients with POD recovers 3 months after surgery, but shows severe deterioration in the long term. This could help explain why an association of EU(7)-PIM with POD was observed, but not with POCD in the descriptive, unadjusted analyses.

Furthermore, pre-existing NCD, reduced functional status, and malnutrition are also considered predisposing risk factors for elderly surgical patients. This could explain why group differences could be observed in descriptive, unadjusted analysis, but not in the logistic regression analysis. Comorbidities are more frequently observed in elderly patients, and medication is often the primary method of treatment. Polypharmacy or medication according to the EU(7)-PIM list may therefore be an expression of these risk factors and help explain the group differences.

Another plausible approach is that patients with pre-existing NCD or frailty are particularly vulnerable to the side effects of drugs and their related toxicity, thus increasing the risk of developing POD or POCD. In the context of polypharmacy, this toxicity-vulnerability interaction might be amplified by drug-drug interactions, the likelihood of potentially inappropriate medication, and the increase of medication discrepancies (mismatch between the medication actually taken by the patient and the medication recorded in the patient’s medical record or medication prescriptions).

Furthermore, although current recommendations call for checking the presence of polypharmacy and to critically review prescription indications (also with regard to potentially inappropriate medication), no general recommendations exists to reduce polypharmacy or the intake of potentially inappropriate medication once identified. The “Primary Medical Care” (Primärmexistische Versorgung [PMV]) Research Group recommends the PRISCUS list “as an aid for critically evaluating medications and not as a list of forbidden drugs.” This recommendation is not yet based on appropriate evidence, but underlines the importance of an individualized treatment of each patient.

Our analysis could not confirm that screening for polypharmacy or the application of the PRISCUS or EU(7)-PIM list can reliably identify patients at risk for development of POD or POCD prior to surgery. Future analyses should therefore adopt other approaches, considering time-dependent effects, dose levels of inappropriate drugs, as well as the impact of bridging of inappropriate or beneficial drugs before surgery, in addition to drug interactions. Furthermore, the association of drugs that are not on these lists, but which are known to cause alterations of the physiological processes, should also be investigated in regard to the development of POD and POCD. These approaches could be applied to verify whether patients benefit from a pre-operative adjustment of long-term medication aimed at reducing possible harmful and toxic drug reactions in patients with high vulnerability.

**Strength and limitations**

A key strength of this study is the prospective multicenter design. In addition, POD and POCD were characterized by a comprehensive, standardized, complex, and validated assessment. For POCD, the neuropsychological test battery covered various cognitive domains, and was carried out following a
well-described standard with limited rater effects. A comprehensible algorithm in R is available to improve comparison of our results with other studies. The study database also contains extensive information on possible confounders. In addition, we were able to investigate the associations over a wide range of surgical disciplines, which reflects the conditions that apply to the pre-operative risk evaluation settings in clinical practice.

Nevertheless, some important limitations must be considered. In our cohort, the incidence of POCD is relatively low with ~10%, which limits the statistical power. The wide range of surgical disciplines increased the study population’s variance in characteristics.

**CONCLUSIONS**

In conclusion, when considering confounders, there were no associations between pre-operative polypharmacy and the intake of potentially inappropriate medications and the development of POD and POCD. However, further studies are needed to determine whether and how patients benefit from a pre-operative adjustment of long-term medication.

**ACKNOWLEDGEMENTS**

The authors thank Konstanze Scheurer (Charité-Universitätsmedizin Berlin) for the administrative support with study coordination and management. Judy Veldhuijzen (UMC Utrecht), Antje Kraft (Charité Universitätsmedizin Berlin), Simone Kühn (University of Hamburg) and Insa Feinkohl (Max-Delbrück Center Berlin) provided additional neuropsychological expertise. Kathrin Scholtz supported the study as the clinical monitor. Data management was provided by Olaf Bender and Alexander Krannich at Koordinierungszentrum für Klinische Studien (KKS Berlin) supported by Pharmaimage Biomarkers Solutions GmbH. Henning Krampe supported the study by recruiting and supervising students for neuropsychological testing. We thank our team of investigators, medical doctoral students and study nurses: Alissa Wolf, Fatima Yürek, Anika Müller, Daniel Hadzidiakos, Ilse Kant, Simone van Montfort, Gunnar Lachmann, Anika Alon, Sina Rosenblender, Tuba Aslan, Markus Laubach, Felix Müller, Emmanuel Keller, Eleftheria Papadaki, Saya Speidel, Bennet Borak, Steffie Herforth, Johannes Lange, Mario Lamping, Helene Michler, Juliane Dörfler, Anton Jacobshagen, Petra Kozma, Marinus Fislage, Wolf Rüdiger Brockhaus, Luisa Rothe, Pola Neuling, Ken-Dieter Michel, Zdravka Bosancic, Firas Nosirat, Maryam Kurpanik, Sophia Kuenz, Lukas Roediger, Irene Mergele, Leopold Rupp, Marie Graunke, and Victoria Windmann. The authors further wish to thank the team of the student and interns of the Department of Anesthesiology at the Charité-Universitätsmedizin Berlin. Maria Heinrich is participant in the BIH-Charité Digital Clinician Scientist Program funded by the Charité–Universitätsmedizin Berlin and the Berlin Institute of Health.

**CONFLICT OF INTEREST**

All authors declared no competing interests for this work.

**AUTHOR CONTRIBUTIONS**

M.H., A.N., F.B., R.M., J.K., G.W., A.J. and C.S. wrote the manuscript. M.H., A.N., G.W., A.J., and C.S. designed the research. M.H., A.N., F.B., and R.M. performed the research. M.H. and J.K. analyzed the data.

**REFERENCES**


SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.